Saizen®    (DrugBank: -)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
78下垂体前葉機能低下症12

78. 下垂体前葉機能低下症 [臨床試験数:462,薬物数:346(DrugBank:45),標的遺伝子数:41,標的パスウェイ数:80
Searched query = "Hypopituitarism", "Anterior pituitary hypothyroidism", "Syndrome of abnormal secretion of gonadotropin", "Hyposecretion of gonadotropins", "Adrenocorticotropic hormone deficiency", "ACTH deficiency", "Thyroid-stimulating hormone deficiency", "TSH deficiency", "Growth hormone deficiency", "GH deficiency", "GHD", "CGHD", "AGHD", "Prolactin deficiency", "PRL deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
12 / 462 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01806298
(ClinicalTrials.gov)
June 20135/3/2013An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD)Open-label, Single-arm, Phase IV, Multicenter Trial to Explore the Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD)Adult Growth Hormone DeficiencyDrug: Saizen® solution for injection (referred as Saizen®)Merck KGaANULLCompleted18 Years65 YearsAll78Phase 4Australia;Germany;Sweden;United Kingdom;Czech Republic
2EUCTR2012-004263-47-CZ
(EUCTR)
13/05/201305/03/2013Exploration if Saizen marketed solution for injection induces an immunogenic reactionOpen-label, single-arm, phase IV, multicenter trial to explore the immunogenicity of the liquid formulation of Saizen® in subjects with adult growth hormone deficiency (AGHD). - Saizen, Phase 4 study in Growth Hormone Deficiency Adult Growth Hormone Deficiency
MedDRA version: 17.1;Level: PT;Classification code 10056438;Term: Growth hormone deficiency;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]
Trade Name: SAIZEN
INN or Proposed INN: Somatropin
Other descriptive name: SOMATROPIN
Merck KGaANULLNot RecruitingFemale: yes
Male: yes
77Phase 4Czech Republic;Australia;Germany;United Kingdom;Sweden
3EUCTR2012-004263-47-DE
(EUCTR)
03/04/201325/02/2013Exploration if Saizen marketed solution for injection induces an immunogenic reactionOpen-label, single-arm, phase IV, multicenter trial to explore the immunogenicity of the liquid formulation of Saizen® in subjects with adult growth hormone deficiency (AGHD) - Saizen, Phase 4 study in Growth Hormone Deficiency Adult Growth Hormone Deficiency
MedDRA version: 17.1;Level: PT;Classification code 10056438;Term: Growth hormone deficiency;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]
Trade Name: SAIZEN
INN or Proposed INN: Somatropin
Other descriptive name: SOMATROPIN
Merck KGaANULLNot RecruitingFemale: yes
Male: yes
77Phase 4Czech Republic;Australia;Germany;United Kingdom;Sweden
4EUCTR2012-004263-47-SE
(EUCTR)
06/03/201314/01/2013Exploration if Saizen marketed solution for injection induces an immunogenic reactionOpen-label, single-arm, phase IV, multicenter trial to explore theimmunogenicity of the liquid formulation of Saizen® in subjects with adult growth hormone deficiency (AGHD) Adult Growth Hormone Deficiency
MedDRA version: 17.1;Level: PT;Classification code 10056438;Term: Growth hormone deficiency;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]
Trade Name: SAIZENMerck KGaANULLNot RecruitingFemale: yes
Male: yes
77Phase 4Czech Republic;Australia;Germany;United Kingdom;Sweden
5EUCTR2012-004263-47-GB
(EUCTR)
01/03/201308/01/2013Exploration if Saizen marketed solution for injection induces an immunogenic reactionOpen-label, single-arm, phase IV, multicenter trial to explore the immunogenicity of the liquid formulation of Saizen® in subjects with adult growth hormone deficiency (AGHD) of adult onset - Saizen, Phase 4 study in Growth Hormone Deficiency Adult Growth Hormone Deficiency
MedDRA version: 17.1;Level: PT;Classification code 10056438;Term: Growth hormone deficiency;System Organ Class: 10014698 - Endocrine disorders ;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]
Merck KGaANULLNot Recruiting Female: yes
Male: yes
77Phase 4Czech Republic;Australia;Germany;United Kingdom;Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT01494779
(ClinicalTrials.gov)
March 201328/11/2011Evaluation of Pharmacokinetic and Pharmacodynamic Parameters of Somatropin Produced by Laboratory Blausiegel Indústria e Comércio Ltda., Compared to Saizen® From Laboratory Merck Serono S.A.GH Deficiency (GHD);Growth RetardationDrug: SomatropinL.A.L Clinica Pesquisa e Desenvolvimento Ltda.NULLNot yet recruiting18 Years32 YearsMale32Phase 1Brazil
7NCT01237340
(ClinicalTrials.gov)
October 20105/11/2010Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity StudyA Phase IIIb, Open-label, Single-arm, Multicenter Study to Assess the Immunogenicity of the Recombinant-Human Growth Hormone (r-hGH) Liquid Multidose Formulation (Saizen® Solution for Injection) When Administered to Male and Female Adults With Documented Growth Hormone Deficiency (GHD)Growth Hormone Deficiency (GHD)Drug: Saizen®EMD SeronoNULLTerminated18 Years60 YearsAll59Phase 3United States
8NCT01187550
(ClinicalTrials.gov)
March 200722/8/2010Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen®A Phase IV Open-label Study of Predictive Markers in Growth Hormone Deficient Pre-pubertal Children Treated With Saizen®Dwarfism, PituitaryDrug: Recombinant human growth hormone (r-hGH)Merck KGaAMerck Serono Co., Ltd., ChinaCompletedN/AN/AAll214Phase 4NULL
9NCT00256126
(ClinicalTrials.gov)
May 31, 200518/11/2005Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN®A Phase IV Open-label Study of Predictive Markers in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children Treated With SAIZEN®Growth Hormone Deficiency;Turner SyndromeDrug: SaizenMerck KGaA, Darmstadt, GermanyNULLCompleted2 Years16 YearsAll318Phase 4Argentina;Australia;Austria;Canada;France;Germany;Italy;Norway;Russian Federation;Singapore;Spain;Sweden;United Kingdom
10NCT00109733
(ClinicalTrials.gov)
January 20052/5/2005Cool.Click™ Adolescent Transition Study: Study of Saizen® in Subjects With Childhood-onset Growth Hormone DeficiencyA Phase IIIb, Prospective, Multicenter, Randomized, Open-label Study to Determine the Safety and Efficacy of Two Different Dosing Regimens of Saizen® (Recombinant Human Growth Hormone (r-hGH), Using Cool.Click™ in Subjects With Childhood-onset Growth Hormone Deficiency During the Adolescent Transition Phase (CATS)Childhood-onset Growth Hormone Deficiency;Pituitary DwarfismBiological: recombinant human growth hormoneEMD SeronoNULLCompleted13 Years25 YearsAll31Phase 3United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT01157793
(ClinicalTrials.gov)
September 20036/7/2010A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to AdulthoodA Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in GHD Subjects During the Transition Phase From Childhood to AdulthoodDwarfism;Growth Hormone DeficiencyDrug: r-hGHMerck KGaANULLCompleted14 Years25 YearsBoth34Phase 4NULL
12EUCTR2015-001569-20-Outside-EU/EEA
(EUCTR)
06/07/2015Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen®A Phase IV Open-label Study of Predictive Markers in Growth Hormone Deficient Pre-pubertal Children Treated With Saizen® Dwarfism, Pituitary
MedDRA version: 18.0;Level: PT;Classification code 10013883;Term: Dwarfism;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]
Trade Name: SaizenMerck Serono Co., Ltd.NULLNAFemale: yes
Male: yes
214Phase 4China